Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy wins WHO approval for three HIV drugs

Ranbaxy says that the World Health Organisation has included the company's three HIV treatments in its pre-qualification list

India-based Ranbaxy has revealed that the World Health Organisation (WHO) has included the company's three HIV treatments in its pre-qualification list.

Ranbaxy says it now has 15 Anti Retroviral products (ARVs) in WHO's pre-qualification list, consisting of single and fixed dose combination products. The products are manufactured at the company's accredited sites in India.

The newly included ARVs are presented in compliance kit packs and are designed to enhance patient compliance for medication and are the latest additions to the WHO list.

The compliance packs contain two fixed dose combination tablets of lamivudine or zidovudine or Stavudine, with a single tablet of efavirenz. Of these, lamivudine or stavudine and efavirenz formulations are the first by any company on the WHO list, said Ranbaxy.

Ranbaxy has already filed a range of ARVs for FDA approval and has begun receiving tentative approvals from the US Federal agency under the President's Emergency Plan For AIDS Relief (PEPFAR) programme.

On 10 September, Ranbaxy's shares traded 1.3 per cent up at INR 415.30 on the Mumbai Stock Exchange.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics